<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The development of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> represents a major complication in patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) </plain></SENT>
<SENT sid="1" pm="."><plain>The importance of microRNAs (miRs) in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> is becoming clearer because miRs have been implicated in the regulation of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related cellular processes to include <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, differentiation, cell cycle progression, and immune function </plain></SENT>
<SENT sid="2" pm="."><plain>In the current study, we sought to identify miR dysregulation specific to progression along the <z:mpath ids='MPATH_458'>normal</z:mpath>-<z:mp ids='MP_0001845'>inflammation</z:mp>-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> axis in colonic specimens from patients with IBD </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: MiR microarrays and quantitative reverse transcription PCR were used to detect and confirm dysregulated miRs </plain></SENT>
<SENT sid="4" pm="."><plain>Receiver operating characteristic curve analysis was applied to evaluate the potential use of miR-224 as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">neoplastic disease</z:e> marker in IBD </plain></SENT>
<SENT sid="5" pm="."><plain>For miR-224 target <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> (<z:chebi fb="2" ids="33699">mRNA</z:chebi>) identification, <z:chebi fb="2" ids="33699">mRNA</z:chebi> microarrays were employed in combination with bioinformatic analyses, Western blotting, and luciferase activity measurements </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: We identified 30 miRs that were differentially expressed between chronically inflamed mucosae and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> arising from IBD tissues </plain></SENT>
<SENT sid="7" pm="."><plain>MiR-224 levels increased successively at each stage of IBD progression and accurately discriminated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> from <z:mpath ids='MPATH_458'>normal</z:mpath> or chronically inflamed IBD tissues </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, <z:chebi fb="2" ids="33699">mRNA</z:chebi> arrays combined with bioinformatic analyses suggested the participation of miR-224 in cell cycle regulation </plain></SENT>
<SENT sid="9" pm="."><plain>Subsequently, cell cycle experiments indicated that miR-224 regulates the G1-S checkpoint </plain></SENT>
<SENT sid="10" pm="."><plain>Finally, in silico prediction analyses, confirmed by Western blotting and luciferase assays, identified p21 as a specific direct <z:chebi fb="2" ids="33699">mRNA</z:chebi> target of miR-224 </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: These findings reveal miR dysregulation specific to IBD-associated colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>MiR-224 is overexpressed in IBD <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and targets p21, a key cell cycle regulator </plain></SENT>
<SENT sid="13" pm="."><plain>Moreover, these results establish the participation of miR-224 in IBD <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
</text></document>